Tesaro, Inc.

When one public company acquires another the conventional wisdom is that the stock prices of acquired and acquirer move in different directions. The most logical move is for the acquired company’s val

Clovis Oncology, Inc. is facing a double-hit for its stumbling PARP inhibitor Rubraca (rucaparib), as it has voluntarily withdrawn an indication for third-line ovarian cancer in the US due to safety

Most of industry's top pharma firms will report fourth quarter sales and earnings results during the two weeks starting 31 January and investors will tune in to hear updates on plans for growth in 202

GlaxoSmithKline plc ’s PD-1 blocking antibody, Jemperli (dostarlimab-gxly), has been approved for a second indication in the US, the treatment of adult patients with mismatch repair-deficient (dMMR) r